Hangzhou Diagens Biotechnology Co (HKSE:02526) Total Liabilities: HK$133.39 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02526 Hangzhou Diagens Biotechnology Co Ltd HKSE:02526
8 GF Score
Price HK$370.00
! 1 Warning Sign
View Full Analysis

What is Hangzhou Diagens Biotechnology Co Total Liabilities?

Hangzhou Diagens Biotechnology Co HKSE:02526 -1.07% 8 Total Liabilities is HK$133.39 Mil as of Jun. 2026. GuruFocus rates HKSE:02526 with a GF Score™ of 8/100. The stock has 1 warning sign investors should review.

Hangzhou Diagens Biotechnology Co's Total Liabilities for the quarter that ended in Jun. 2026 was HK$133.39 Mil.

Hangzhou Diagens Biotechnology Co's quarterly Total Liabilities increased from Sep. 2025 (HK$52.46 Mil) to Dec. 2025 (HK$55.07 Mil) and increased from Dec. 2025 (HK$55.07 Mil) to Jun. 2026 (HK$133.39 Mil).

Hangzhou Diagens Biotechnology Co's annual Total Liabilities declined from Dec. 2023 (HK$335.47 Mil) to Dec. 2024 (HK$40.88 Mil) but then increased from Dec. 2024 (HK$40.88 Mil) to Dec. 2025 (HK$55.07 Mil).

Hangzhou Diagens Biotechnology Co Total Liabilities Historical Data

* Premium members only.

The historical data trend for Hangzhou Diagens Biotechnology Co's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hangzhou Diagens Biotechnology Co Total Liabilities Chart

Hangzhou Diagens Biotechnology Co Annual Data
Trend Dec23 Dec24 Dec25
Total Liabilities
335.47 40.88 55.07

Hangzhou Diagens Biotechnology Co Quarterly Data
Dec23 Dec24 Sep25 Dec25 Jun26
Total Liabilities 335.47 40.88 52.46 55.07 133.39
HKSE:02526
8GF Score
Hangzhou Diagens Biotechnology Co Ltd HKSE:02526
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hangzhou Diagens Biotechnology Co Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Hangzhou Diagens Biotechnology Co's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=49.887+(4.913+0.271
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=55.07

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=238.154-183.084
=55.07

Hangzhou Diagens Biotechnology Co's Total Liabilities for the quarter that ended in Jun. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=128.413+(4.969+0.0069999999999988
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=133.39

Total Liabilities=Total Assets (Q: Jun. 2026 )-Total Equity (Q: Jun. 2026 )
=1029.906-896.517
=133.39

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of HK$133.39 Mil mean?
Hangzhou Diagens Biotechnology Co (HKSE:02526) has a Total Liabilities of HK$133.39 Mil as of Jun. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Hangzhou Diagens Biotechnology Co and its competitors.
Is Hangzhou Diagens Biotechnology Co's Total Liabilities too high?
Hangzhou Diagens Biotechnology Co's current Total Liabilities is HK$133.39 Mil. Overall, Hangzhou Diagens Biotechnology Co has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Hangzhou Diagens Biotechnology Co's Total Liabilities compare to ABT and SYK?
Hangzhou Diagens Biotechnology Co's Total Liabilities of HK$133.39 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Medical Devices & Instruments company?
A good Total Liabilities depends on the Medical Devices & Instruments industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Hangzhou Diagens Biotechnology Co and its competitors. Hangzhou Diagens Biotechnology Co's current Total Liabilities is HK$133.39 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hangzhou Diagens Biotechnology Co stock overvalued right now?
Hangzhou Diagens Biotechnology Co (HKSE:02526) has a current Total Liabilities of HK$133.39 Mil. The current Total Liabilities is HK$133.39 Mil. Hangzhou Diagens Biotechnology Co's overall GF Score™ is 8/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Hangzhou Diagens Biotechnology Co (HKSE:02526), the current Total Liabilities is HK$133.39 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Hangzhou Diagens Biotechnology Co Business Description

Address No. 609 Hongfeng Road, Room 101, Building 1, Donghu Sub-district, Linping District, Zhejiang, Hangzhou, CHN
Hangzhou Diagens Biotechnology Co Ltd and its subsidiaries are involved in the development and commercialisation of medical imaging artificial intelligence technologies and medical imaging equipment. It has self-developed a diversified portfolio, including six medical imaging software products, three commercialized medical devices, four key reagents and consumables and two technology licensing offerings. Its Core Product, AI AutoVision, is an auxiliary diagnostic software designed to undertake intelligent analysis on chromosome karyotyping. The majority of the company's revenue is derived from Technology Licensing, mainly in the Chinese mainland.
8GF Score

Get the complete analysis for HKSE:02526

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$370.00
Price